BioVersys AG (SWX:BIOV)
Switzerland
· Delayed Price · Currency is CHF
27.00
+1.80 (7.14%)
At close: Aug 14, 2025, 5:20 PM CET
BioVersys AG Income Statement
Financials in millions CHF. Fiscal year is January - December.
Millions CHF. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Other Revenue | 1.21 | 1.14 |
| Revenue | 1.21 | 1.14 |
| Revenue Growth (YoY) | 6.50% | - |
| Gross Profit | 1.21 | 1.14 |
| Selling, General & Admin | 7 | 4.02 |
| Research & Development | 12.95 | 14.83 |
| Operating Expenses | 19.94 | 18.84 |
| Operating Income | -18.73 | -17.7 |
| Interest Expense | -1.03 | -0.7 |
| Interest & Investment Income | 0.5 | 0.48 |
| Currency Exchange Gain (Loss) | 0.13 | -0.16 |
| Other Non Operating Income (Expenses) | 0.42 | -0.22 |
| Pretax Income | -18.72 | -18.3 |
| Net Income | -18.72 | -18.3 |
| Net Income to Common | -18.72 | -18.3 |
| Shares Outstanding (Basic) | 3 | 3 |
| Shares Outstanding (Diluted) | 3 | 3 |
| Shares Change (YoY) | 11.60% | - |
| EPS (Basic) | -5.62 | -6.13 |
| EPS (Diluted) | -5.62 | -6.13 |
| Free Cash Flow | -15.61 | -11.7 |
| Free Cash Flow Per Share | -4.68 | -3.92 |
| Gross Margin | 100.00% | 100.00% |
| Operating Margin | -1544.11% | -1554.17% |
| Profit Margin | -1543.20% | -1606.76% |
| Free Cash Flow Margin | -1287.06% | -1027.57% |
| EBITDA | -18.67 | -17.65 |
| D&A For EBITDA | 0.06 | 0.06 |
| EBIT | -18.73 | -17.7 |
| Revenue as Reported | 1.21 | 1.14 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.